- Home
- GLTO
GLTO
Galecto Inc.
as of 01-28-2026 3:52pm EST
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
| Founded: | 2011 | Country: | Denmark |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 54.5M | IPO Year: | 2020 |
| Target Price: | $41.00 | AVG Volume (30 days): | 37.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $38.33 | Next Earning Date: | 03-18-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered GLTO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Galecto Inc. (GLTO)
General Counsel
Avg Cost/Share
$21.38
Shares
255
Total Value
$5,451.90
Owned After
1,854
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$21.38
Shares
700
Total Value
$14,966.00
Owned After
4,682
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$21.41
Shares
135
Total Value
$2,890.35
Owned After
931
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Winslow Garrett | GLTO | General Counsel | Jan 2, 2026 | Sell | $21.38 | 255 | $5,451.90 | 1,854 | |
| Schambye Hans T. | GLTO | Chief Executive Officer | Jan 2, 2026 | Sell | $21.38 | 700 | $14,966.00 | 4,682 | |
| Firmani Lori | GLTO | Chief Financial Officer | Jan 2, 2026 | Sell | $21.41 | 135 | $2,890.35 | 931 |
Compare GLTO vs Leading Stocks
See how GLTO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GLTO Galecto Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.